- Bimeda to launch Gastrobim™, a bioequivalent omeprazole product, in the U.S.
- First FDA-approved bioequivalent to GastroGard® for equine gastric ulcers
- Apple-flavored formulation designed for ease of administration
- Targets Equine Gastric Ulcer Syndrome (EGUS) in horses and foals
- Aims to improve affordability and access to proven ulcer treatments
- Builds on strong adoption in Canada and Europe
Bimeda has announced plans to launch Gastrobim™ (omeprazole) in the United States, marking the first FDA-approved bioequivalent to GastroGard® for the treatment and prevention of equine gastric ulcers.
The product is indicated for use in horses and foals four weeks of age and older, offering a clinically equivalent alternative for managing Equine Gastric Ulcer Syndrome (EGUS), a common condition that can impact performance and overall health.
Expanding Access to Proven Treatment
Gastrobim™ is designed to provide veterinarians and horse owners with a high-quality, more accessible option for ulcer management. The apple-flavored formulation is intended to improve palatability and ease of administration, supporting compliance in both clinical and field settings.
The launch follows strong adoption in international markets, where the product has gained traction for its effectiveness in treating and healing gastric ulcers.
Addressing a Common Performance Issue
EGUS affects a significant proportion of performance horses and is associated with reduced appetite, behavioral changes, discomfort, and decreased athletic performance.
By introducing a bioequivalent alternative, Bimeda aims to broaden treatment access while maintaining clinical efficacy, helping improve health outcomes across the equine industry.
“We are thrilled to introduce Gastrobim™ to the U.S. market,” said Eric Moore, DVM, Head of Technical Services North America at Bimeda. “Providing a rigorously tested, bioequivalent treatment underscores our commitment to supporting equine health, welfare, and performance at an affordable price.”
Strengthening Equine Portfolio
The addition of Gastrobim™ further expands Bimeda’s equine product portfolio, which includes established brands across pharmaceuticals and health solutions.
The company said the launch reflects its ongoing focus on delivering innovative, cost-effective therapies to meet the needs of veterinarians, trainers, and horse owners.
Gastrobim™ is expected to begin shipping nationwide through animal health distributors in the near term.
Information sourced from the company’s press release.
